Search

Your search keyword '"Thomas Adam"' showing total 42 results
Start Over Author "Thomas Adam" Journal journal of clinical oncology
42 results on '"Thomas Adam"'

2. Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.

Author

Goyal, Lipika, primary, Meric-Bernstam, Funda, additional, Hollebecque, Antoine, additional, Morizane, Chigusa, additional, Valle, Juan W., additional, Karasic, Thomas Benjamin, additional, Abrams, Thomas Adam, additional, Kelley, Robin Kate, additional, Cassier, Philippe Alexandre, additional, Furuse, Junji, additional, Klümpen, Heinz-Josef, additional, Chang, Heung-Moon, additional, Chen, Li-Tzong, additional, Komatsu, Yoshito, additional, Masuda, Kunihiro, additional, Ahn, Daniel H., additional, Li, Kate, additional, Benhadji, Karim A., additional, Wacheck, Volker, additional, and Bridgewater, John A., additional

Published
2022
Full Text
View/download PDF

3. Final results of a phase 1b/2 study of tivozanib in combination with durvalumab in patients with advanced hepatocellular carcinoma in both previously untreated patients and patients progressing on atezolizumab and bevacizumab

Author

Daneng Li, Farshid Dayyani, Devalingam Mahalingam, Julie Haewon Rowe, Thomas Adam Abrams, Vijay Kasturi, and Renuka V. Iyer

Subjects
Cancer Research, Oncology
Abstract

585 Background: The approval of atezolizumab + bevacizumab for untreated advanced HCC was a significant benefit for patients, but with an increased risk of potentially severe bleeding complications. Tivozanib (a selective VEGFR 1, 2, & 3 tyrosine kinase inhibitor [TKI]) has been combined with durvalumab in the DEDUCTIVE study; preliminary results presented in January 2022 showed that this combination was well tolerated with comparable efficacy to other immune checkpoint and VEGF containing regimens in patients with previously untreated HCC ( J Clin Oncol 40, no. 4 suppl 462-462). We now report the final results of this cohort (cohort A) of patients as well as those with previously treated HCC, including safety results for all the patients. Methods: Major eligibility criteria included age >18 yrs with documented advanced HCC, Child-Pugh Class A, ECOG 0 or 1, and creatinine clearance >40 ml/min. Major exclusion criteria included co-infection with HBV and HCV and significant organ dysfunction. Patients were treated with 0.89 mg tivozanib p.o., 21 days on followed by 7 days off and 1500 mg durvalumab i.v. every 28 days. The primary objective was to determine the safety and tolerability of this combination in patients with advanced HCC; secondary objectives included assessing objective response rate (ORR), progression free survival, and overall survival (OS). The study was amended in 2021 to include a cohort of patients previously treated with atezolizumab and bevacizumab (cohort B). Results: 21 patients were enrolled in cohort A and 6 in cohort B; the median age was 67, 88% of patients were male, and 24% were Asian. The median follow-up time was 13.2 mos and 3.4 mos for cohorts A and B, respectively. Data were available for 25 of the 27 patients enrolled. For cohort A, the ORR was 25% (5/20) and 1-year OS was 76%. For safety analysis, 24 (96%) patients had at least 1 treatment-emergent adverse event (TEAE); 92% were attributed possibly to either tivozanib or durvalumab; 32% were serious TEAEs and there was 1 TEAE leading to death (unrelated). Of the 8 (32%) serious TEAE, 2 were coronavirus infection. 2 patients had serious (grade 3) treatment-related AEs: 1 pneumonitis and 1 with gastrointestinal hemorrhage and anemia. There were no grade 4 or 5 treatment-related AEs. Conclusions: Treatment with the combination of tivozanib and durvalumab in patients with either untreated advanced HCC or those previously treated with atezolizumab and bevacizumab was well tolerated; no severe bleeding events occurred in this study. Efficacy outcomes were comparable to other IO-TKI combinations in HCC. Data for PDL1 status, HBV/HCV status was collected and will be presented along with final safety and efficacy results for both cohorts. Clinical trial information: NCT03970616 .

Published
2023
Full Text
View/download PDF

4. A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort.

Author

Abrams, Thomas Adam, primary, Kazmi, Syed Mohammad Ali, additional, Winer, Ira Seth, additional, Subbiah, Vivek, additional, Falchook, Gerald Steven, additional, Reilley, Matthew, additional, Kunk, Paul Raymond, additional, Goel, Sanjay, additional, Garrido-Laguna, Ignacio, additional, Kochenderfer, Mark D., additional, Werneke, Scott, additional, Andrianova, Lana, additional, Sudhagoni, Ramu, additional, and Paulson, Scott, additional

Published
2022
Full Text
View/download PDF

6. Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements

Author

Lipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, Chigusa Morizane, Juan W. Valle, Thomas Benjamin Karasic, Thomas Adam Abrams, Robin Kate Kelley, Philippe Alexandre Cassier, Junji Furuse, Heinz-Josef Klümpen, Heung-Moon Chang, Li-Tzong Chen, Yoshito Komatsu, Kunihiro Masuda, Daniel H. Ahn, Kate Li, Karim A. Benhadji, Volker Wacheck, and John A. Bridgewater

Subjects
Cancer Research, Oncology
Abstract

4009 Background: Survival outcomes are historically poor in patients (pts) with advanced/metastatic iCCA, with median overall survival (mOS) times of approximately 1 year with first-line gemcitabine plus cisplatin and approximately 6 months with second-line chemotherapy. Futibatinib, a highly selective, irreversible FGFR1–4 inhibitor, demonstrated efficacy with durable responses in pts with iCCA harboring FGFR2 fusion/rearrangements in the pivotal FOENIX-CCA2 phase 2 study (NCT02052778). At the primary analysis of this trial (data cutoff: October 1, 2020), an objective response rate (ORR) of 41.7% was observed, with a median duration of response (mDOR) of 9.7 mo. Here, we report updated efficacy (including mature OS data) and safety data from the final analysis with an additional 8 mo of follow-up. Methods: FOENIX-CCA2 was a single-arm phase 2 study that enrolled pts with advanced/metastatic iCCA with FGFR2 fusion/rearrangement and progressive disease (PD) after ≥1 prior treatment (tx; including gemcitabine plus platinum-based chemotherapy). Pts received futibatinib 20 mg once daily until PD/intolerability. The primary endpoint was ORR per RECIST v1.1 by independent central review. Secondary endpoints were DOR, disease control rate (DCR), progression-free survival (PFS), OS, safety, and patient-reported outcomes. Results: At the time of the final data cutoff (May 29, 2021), median follow-up was 25.0 mo, and 96/103 pts (93%) had discontinued tx. The median number of tx cycles was 13.0 for a median tx duration of 9.1 mo. The confirmed ORR was 41.7% (43/103) and thereby the same as of the primary analysis, as was the DCR (at 82.5%). The ORR was consistent across pt subgroups. The mDOR was 9.5 mo, and 74% of responses lasted ≥6 mo. mPFS was 8.9 mo, with a 12-mo PFS rate of 35.4%. Mature mOS was 20.0 mo, with a 12-mo OS rate of 73.1% . No new safety signals were identified. Common tx-related adverse events (TRAEs) included hyperphosphatemia (85%), alopecia (33%), dry mouth (30%), diarrhea (28%), dry skin (27%), and fatigue (25%). TRAEs resulted in tx discontinuation in 4 pts (4%). No tx-related deaths occurred. Quality of life was maintained from baseline to tx cycle 13. Conclusions: Findings from the final analysis of FOENIX-CCA2 confirm the results of the primary analysis and reinforce the durable efficacy and continued tolerability of futibatinib in previously treated pts with advanced/metastatic iCCA harboring FGFR2 fusion/rearrangements. Mature OS data were consistent with data from the primary analysis and far exceed historical data in this patient population. Clinical trial information: NCT02052778.

Published
2022
Full Text
View/download PDF

7. A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors.

Author

Burris III, Howard A., primary, Spira, Alexander I., additional, Taylor, Matthew H., additional, Yeku, Oladapo O., additional, Liu, Joyce F., additional, Munster, Pamela N., additional, Hamilton, Erika P., additional, Thomas, Jacob Stephen, additional, Gatlin, Frances, additional, Penson, Richard T., additional, Abrams, Thomas Adam, additional, Dhawan, Mallika Sachdev, additional, Walling, Jacqueline M., additional, Frye, John W., additional, Romanko, Kevin, additional, Sung, Victoria, additional, Brachmann, Carrie, additional, and El-Khoueiry, Anthony B., additional

Published
2021
Full Text
View/download PDF

8. A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort

Author

Thomas Adam Abrams, Syed Mohammad Ali Kazmi, Ira Seth Winer, Vivek Subbiah, Gerald Steven Falchook, Matthew Reilley, Paul Raymond Kunk, Sanjay Goel, Ignacio Garrido-Laguna, Mark D. Kochenderfer, Scott Werneke, Lana Andrianova, Ramu Sudhagoni, and Scott Paulson

Subjects
Cancer Research, Oncology
Abstract

121 Background: Cabozantinib, a multiple receptor tyrosine kinase inhibitor, promotes an immune-permissive environment which may enhance the activity of immune checkpoint inhibitors. COSMIC-021 (NCT03170960) is evaluating the combination of cabozantinib with atezolizumab, an anti-PD-L1 inhibitor, in patients with advanced solid tumors. Outcomes in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-containing therapy are presented. Methods: Pts with mCRC and an ECOG PS of 0–1 who progressed during or following systemic chemotherapy including fluoropyrimidine plus oxaliplatin or irinotecan were eligible. Up to 2 prior lines of anti-cancer therapy including EGFR-targeted therapy were allowed. Microsatellite instability high (MSI-H) and/or mismatch repair (MMR)-deficient pts were excluded. Pts received cabozantinib 40 mg PO QD plus atezolizumab 1200 mg IV Q3W. The primary endpoint was objective response rate (ORR) per RECIST 1.1 by investigator. Other endpoints included safety, duration of response (DOR), progression-free survival (PFS), and overall survival (OS). CT/MRI scans were performed Q6W for the first year and Q12W thereafter. Results: 31 pts received cabozantinib plus atezolizumab (median age, 60 y [range 31, 79]; male, 58%; ECOG PS 1, 61%; 2 prior lines of therapy, 71%; prior EGFR inhibitor, 16%; ≥3 tumor sites, 52%; tumors in left colorectum, 71%). Median follow-up was 28.1 mo (range, 24.2, 31.3) as of July 21, 2021. Cabozantinib plus atezolizumab demonstrated clinical activity in pts with mCRC (Table). Patients with wild-type RAS (n = 12) had numerically longer PFS and OS and higher ORR vs those with mutations (n = 19) (Table). Treatment-related adverse events (TRAEs) of any grade occurred in 28 (90%); the most common were diarrhea (52%), fatigue (42%), and nausea (35%). Grade 3-4 TRAEs occurred in 16 (52%); the most common were hypertension (10%), fatigue (6%), and lipase increased (6%); no Grade 5 events were reported. Conclusions: Cabozantinib plus atezolizumab demonstrated encouraging clinical activity with manageable toxicity in pts with previously treated advanced non-MSI-H/MMR-proficient CRC. Clinical trial information: NCT03170960. [Table: see text]

Published
2022
Full Text
View/download PDF

9. Phase 1b/2 study of tivozanib in combination with durvalumab in subjects with advanced hepatocellular carcinoma (Deductive): Efficacy results in previously untreated patients

Author

Renuka V. Iyer, Daneng Li, Farshid Dayyani, Julie Haewon Rowe, Muhammad Shaalan Beg, Vijay Kasturi, and Thomas Adam Abrams

Subjects
Cancer Research, Oncology
Abstract

462 Background: The combination of a checkpoint inhibitor, atezolizumab, and angiogenesis inhibitor, bevacizumab, has improved the standard of care in advanced hepatocellular cancer with a median PFS of 6.8 months and 1-year overall survival of 67.2%. Tivozanib (a selective VEGFR 1,2 &3 TKI) has been combined with durvalumab in the phase I portion of the Deductive study (N=7) and the combination was well tolerated with the most common AEs being anorexia, cough, diarrhea, dysphonia, fatigue, hypertension and palmar-plantar erythrodysesthesia. (Ref: Iyer et al, JCO 39(3):294). Two of seven patients achieved a confirmed partial response. Here we report the preliminary efficacy data (PFS and OS) after 1 year of follow up of these patients. Methods: Major eligibility criteria included patients with age ≥18 yrs with documented advanced HCC, Child-Pugh Class A, ECOG 0 or 1, creatinine clearance > 40 ml/min. Major exclusion criteria included co-infection with HBV and HCV and significant organ dysfunction. The primary objective was to establish the RP2D and to determine the safety and tolerability for this combination in patients with advanced HCC. Secondary objectives included assessment of the ORR, PFS, and OS in this population. Results: Seven patients were enrolled in phase I part of the study. Two of seven patients achieved a confirmed partial response. Median PFS in this patient group was 7 months and 1-year survival was 80%. Kaplan-Meier plots of PFS and OS will be shown for patients with previously untreated advanced HCC. Conclusions: The combination of tivozanib and durvalumab in patients with untreated advanced HCC was considered tolerable and resulted in a median PFS of 7 months and 1-year overall survival of 80%. This is comparable to the outcomes seen with atezolizumab and bevacizumab. Enrollment is nearly complete with 19 of 20 patients in the front-line cohort enrolled; a second cohort of 20 patients who have progressed on prior bevacizumab and atezolizumab has been opened and is also enrolling. Data for the first line cohort will be presented at the meeting. Clinical trial information: NCT03970616.

Published
2022
Full Text
View/download PDF

10. A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).

Author

He, Aiwu Ruth, primary, Kim, Alexander Y., additional, Toskich, Beau M, additional, Mody, Kabir, additional, Kim, Kevin, additional, Stein, Stacey, additional, Goyal, Lipika, additional, Abrams, Thomas Adam, additional, Brown, Daniel, additional, Goff, Laura Williams, additional, Kim, Richard D., additional, Parikh, Nainesh, additional, Sandow, Tyler, additional, Johnson, Daniel, additional, Iyer, Renuka V., additional, Petroziello, Michael, additional, Krishnamurthi, Smitha S., additional, Martin, Charles, additional, Jiang, Yixing, additional, and Akhter, Nabeel, additional

Published
2021
Full Text
View/download PDF

13. FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.

Author

Goyal, Lipika, primary, Meric-Bernstam, Funda, additional, Hollebecque, Antoine, additional, Valle, Juan W., additional, Morizane, Chigusa, additional, Karasic, Thomas Benjamin, additional, Abrams, Thomas Adam, additional, Furuse, Junji, additional, He, Yaohua, additional, Soni, Nital, additional, Benhadji, Karim A., additional, and Bridgewater, John A., additional

Published
2020
Full Text
View/download PDF

14. Phase Ib study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.

Author

Perez, Kimberly, primary, Weekes, Colin D., additional, Cleary, James M., additional, Abrams, Thomas Adam, additional, Blaszkowsky, Lawrence Scott, additional, Enzinger, Peter C., additional, Giannakis, Marios, additional, Goyal, Lipika, additional, Meyerhardt, Jeffrey A., additional, Rubinson, Douglas Adam, additional, Yurgelun, Matthew B., additional, Stonely, Danielle, additional, Raghavan, Srivatsan, additional, Bakir, Basil, additional, Das, Koushik, additional, Pitarresi, Jason, additional, Aguirre, Andrew, additional, Needle, Michael N., additional, Rustgi, Anil, additional, and Wolpin, Brian M., additional

Published
2020
Full Text
View/download PDF

15. Phase 1b study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.

Author

Perez, Kimberly, primary, Rubinson, Douglas Adam, additional, Cleary, James M., additional, Meyerhardt, Jeffrey A., additional, Patel, Anuj K., additional, Abrams, Thomas Adam, additional, Rahma, Osama E., additional, Raghavan, Srivatsan, additional, Aguirre, Andrew, additional, Needle, Michael N., additional, Das, Koushik, additional, Pitarresi, Jason, additional, Bakir, Basil, additional, Rustgi, Anil K., additional, and Wolpin, Brian M., additional

Published
2018
Full Text
View/download PDF

16. Implementing universal genetic counseling (GC) and multigene germline testing (MGT) for pancreatic cancer (PC) patients (pts).

Author

Yurgelun, Matthew B., primary, Chittenden, Anu B., additional, Ukaegbu, Chinedu I., additional, Dhingra, Tara G., additional, Gaonkar, Shraddha, additional, Sotelo, Jiliane, additional, Rubinson, Douglas Adam, additional, McCleary, Nadine Jackson, additional, Clancy, Thomas E., additional, Abrams, Thomas Adam, additional, Cleary, James M., additional, Madigan, Audrey P., additional, Brais, Lauren K., additional, Perez, Kimberly, additional, Wolpin, Brian M., additional, and Syngal, Sapna, additional

Published
2018
Full Text
View/download PDF

17. A phase 2 and biomarker study of sorafenib combined with FOLFOX in patients with advanced hepatocellular carcinoma (HCC).

Author

Goyal, Lipika, primary, Zheng, Hui, additional, Abrams, Thomas Adam, additional, Miksad, Rebecca A., additional, Bullock, Andrea J., additional, Allen, Jill N., additional, Yurgelun, Matthew B., additional, Sheehan, Susan, additional, Lynch, Patricia, additional, Afflitto, Anthony James, additional, Dinicola, Caroline, additional, Maurer, Jordan Robert, additional, Reyes, Stephanie, additional, Knowles, Michelle, additional, Galway, Aralee, additional, Clark, Jeffrey W., additional, Birnbaum, Emilie, additional, Khachatryan, Anna, additional, Duda, Gabriel Dan, additional, and Zhu, Andrew X., additional

Published
2018
Full Text
View/download PDF

19. A phase 2 trial of CRS-207 and pembrolizumab in adults with recurrence of metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinomas.

Author

Kelly, Ronan Joseph, primary, Abrams, Thomas Adam, additional, Catenacci, Daniel V.T., additional, Wainberg, Zev A., additional, Lin, Bruce Shih-Li, additional, Enstrom, Amanda, additional, Whiting, Chan C., additional, Wason, Prieya, additional, Murphy, Aimee, additional, Brockstedt, Dirk G., additional, Moon, Anne, additional, Walling, Jackie, additional, Lai, Rose, additional, and Ku, Geoffrey Yuyat, additional

Published
2018
Full Text
View/download PDF

21. SUNSHINE: Randomized double-blind phase II trial of vitamin D supplementation in patients with previously untreated metastatic colorectal cancer.

Author

Ng, Kimmie, primary, Nimeiri, Halla Sayed, additional, McCleary, Nadine Jackson, additional, Abrams, Thomas Adam, additional, Yurgelun, Matthew B., additional, Cleary, James M., additional, Rubinson, Douglas Adam, additional, Schrag, Deborah, additional, Allen, Jill N., additional, Zuckerman, Dan Sayam, additional, Miksad, Rebecca A., additional, Chan, Emily, additional, Constantine, Michael, additional, Weckstein, Douglas, additional, Faggen, Meredith Gail, additional, Thomas, Christian A., additional, Kournioti, Chryssanthi S., additional, Mackintosh, Christopher, additional, Zheng, Hui, additional, and Fuchs, Charles S., additional

Published
2017
Full Text
View/download PDF

22. A phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) for first-line therapy with advanced biliary tract cancer (BTC).

Author

Eads, Jennifer Rachel, primary, Stein, Stacey, additional, El-Khoueiry, Anthony B., additional, Manji, Gulam Abbas, additional, Abrams, Thomas Adam, additional, Khorana, Alok A., additional, Miksad, Rebecca A., additional, Mahalingam, Devalingam, additional, Sirard, Cynthia A., additional, Zhu, Andrew X., additional, and Goyal, Lipika, additional

Published
2017
Full Text
View/download PDF

23. Multicenter, randomized phase II trial of physical activity (PA), metformin (Met), or the combination on metabolic biomarkers in stage I-III colorectal (CRC) and breast cancer (BC) survivors.

Author

Meyerhardt, Jeffrey A., primary, Irwin, Melinda L, additional, Jones, Lee, additional, Zhang, Sui, additional, Campbell, Nancy, additional, Brown, Justin C., additional, Pollak, Michael N., additional, Sorrentino, Alexandra, additional, Cartmel, Brenda, additional, Harrigan, Maura, additional, West, Miranda, additional, Tolaney, Sara M., additional, Yung, Rachel Lynn, additional, Winer, Eric P., additional, Ng, Kimmie, additional, Abrams, Thomas Adam, additional, Fuchs, Charles S., additional, Sanft, Tara Beth, additional, Douglas, Pamela, additional, and Ligibel, Jennifer A., additional

Published
2017
Full Text
View/download PDF

24. Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET).

Author

Chan, Jennifer A., primary, Faris, Jason Edward, additional, Murphy, Janet E., additional, Blaszkowsky, Lawrence Scott, additional, Kwak, Eunice Lee, additional, McCleary, Nadine Jackson, additional, Fuchs, Charles S., additional, Meyerhardt, Jeffrey A., additional, Ng, Kimmie, additional, Zhu, Andrew X., additional, Abrams, Thomas Adam, additional, Wolpin, Brian M., additional, Zhang, Sui, additional, Reardon, Amanda, additional, Fitzpatrick, Bridget, additional, Kulke, Matthew H., additional, and Ryan, David P., additional

Published
2017
Full Text
View/download PDF

26. Virtual consults: A paradigm shift for second opinions in oncology care.

Author

Velis, Stephanie A., primary, Dreyer, Nicholas J, additional, Andersen, Neil, additional, Mayer, Erica L., additional, Davids, Matthew Steven, additional, Abrams, Thomas Adam, additional, Choueiri, Toni K., additional, Meyerhardt, Jeffrey A., additional, Fisher, David Christopher, additional, Lathan, Christopher S., additional, Campos, Susana M., additional, Lane, Susan, additional, and Glynn, Philip T., additional

Published
2016
Full Text
View/download PDF

28. Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA).

Author

Enzinger, Peter C., primary, McCleary, Nadine Jackson, additional, Zheng, Hui, additional, Abrams, Thomas Adam, additional, Yurgelun, Matthew B., additional, Azzoli, Christopher G., additional, Cleary, James M., additional, Rubinson, Douglas Adam, additional, Brooks, Gabriel, additional, Chan, Jennifer A., additional, Goyal, Lipika, additional, Meyerhardt, Jeffrey A., additional, Ng, Kimmie, additional, Schrag, Deborah, additional, Savarese, Diane M. F., additional, Graham, Christopher, additional, Carey, Margaret M., additional, and Fuchs, Charles S., additional

Published
2016
Full Text
View/download PDF

29. A phase II and biomarker study of cabozantinib (XL-184) in patients (pts) with advanced cholangiocarcinoma (CCA).

Author

Goyal, Lipika, primary, Zheng, Hui, additional, Yurgelun, Matthew, additional, Abrams, Thomas Adam, additional, Kwak, Eunice Lee, additional, Cleary, James M., additional, Knowles, Michelle, additional, Regan, Eileen, additional, Gisondi, Amy, additional, Sheehan, Susan, additional, Khachatryan, Anna, additional, Nardi, Valentina, additional, Borger, Darrell R., additional, Duda, Gabriel Dan, additional, and Zhu, Andrew X., additional

Published
2015
Full Text
View/download PDF

30. Multicenter phase 2: Capecitabine (CAP) + oxaliplatin (OX) + bevacizumab (BEV) + trastuzumab (TRAS) for patients (pts) with metastatic esophagogastric cancer (MEGCA).

Author

Enzinger, Peter C., primary, Abrams, Thomas Adam, additional, Chan, Jennifer A., additional, McCleary, Nadine Jackson, additional, Zheng, Hui, additional, Kwak, Eunice Lee, additional, Yurgelun, Matthew, additional, Blaszkowsky, Lawrence Scott, additional, Cleary, James M., additional, Wolpin, Brian M., additional, Meyerhardt, Jeffrey A., additional, Regan, Eileen, additional, Graham, Christopher, additional, Straw, Katharine, additional, Fuchs, Charles S., additional, and Kelly, Ronan Joseph, additional

Published
2015
Full Text
View/download PDF

31. Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer.

Author

Jonker, Derek J., primary, Laurie, Scott Andrew, additional, Cote, Gregory Michael, additional, Flaherty, Keith, additional, Fuchs, Charles S., additional, Chugh, Rashmi, additional, Smith, David C., additional, Edenfield, William Jeffery, additional, Conkling, Paul R., additional, Mier, James Walter, additional, Goodwin, Rachel Anne, additional, Kwak, Eunice Lee, additional, Abrams, Thomas Adam, additional, Goel, Rakesh, additional, Cleary, James M., additional, Li, Wei, additional, Li, Youzhi, additional, Jemison, Jamileh, additional, Hitron, Matthew, additional, and Li, Chiang, additional

Published
2015
Full Text
View/download PDF

34. A single-arm phase II trial of gemcitabine, oxaliplatin, and panitumumab in KRAS wild-type advanced biliary tract cancer.

Author

Noel, Marcus Smith, primary, Allen, Jill N., additional, Abrams, Thomas Adam, additional, Yurgelun, Matthew, additional, Faris, Jason Edward, additional, Goyal, Lipika, additional, Clark, Jeffrey W., additional, Blaszkowsky, Lawrence Scott, additional, Murphy, Janet E., additional, Zheng, Hui, additional, Khorana, Alok A., additional, Connolly, Gregory Clayton, additional, Hyrien, Ollivier, additional, Ng, Kimmie, additional, Borger, Darrell R., additional, Iafrate, Anthony John, additional, Hezel, Aram F., additional, and Zhu, Andrew X., additional

Published
2014
Full Text
View/download PDF

35. A phase II clinical trial of ganetespib (STA-9090) in previously treated patients with advanced esophagogastric cancers.

Author

Kwak, Eunice Lee, primary, Goyal, Lipika, additional, Abrams, Thomas Adam, additional, Carpenter, Amanda, additional, Wolpin, Brian M., additional, Wadlow, Raymond Couric, additional, Allen, Jill N., additional, Heist, Rebecca Suk, additional, McCleary, Nadine Jackson, additional, Chan, Jennifer A., additional, Goessling, Wolfram, additional, Schrag, Deborah, additional, Evans, Colleen, additional, Ng, Kimmie, additional, Enzinger, Peter C., additional, and Ryan, David P., additional

Published
2013
Full Text
View/download PDF

36. Multicenter randomized phase II trial of cisplatin, irinotecan plus bevacizumab (PCA) versus docetaxel, cisplatin, irinotecan plus bevacizumab (TPCA) in patients (pts) with metastatic esophagogastric cancer (MEGCA).

Author

Enzinger, Peter C., primary, Kwak, Eunice Lee, additional, Szymonifka, Jackie, additional, Abrams, Thomas Adam, additional, Regan, Eileen, additional, Malinowski, Paige, additional, Shih, Kent C., additional, Allen, Jill N., additional, Jackson, Nadine, additional, Chan, Jennifer A., additional, Fidias, Panos, additional, Ryan, David P., additional, Fuchs, Charles S., additional, and Bendell, Johanna C., additional

Published
2012
Full Text
View/download PDF

37. Feasibility of computer-based self-administered cancer-specific geriatric assessment (SA-CSGA) in older pts with gastrointestinal malignancy (GIM).

Author

McCleary, Nadine Jackson, primary, Wigler, Devin, additional, Berry, Donna Lynn, additional, Sato, Kaori, additional, Hurria, Arti, additional, Ng, Kimmie, additional, Abrams, Thomas Adam, additional, Chan, Jennifer A., additional, Enzinger, Peter C., additional, Fuchs, Charles S., additional, Wolpin, Brian M., additional, Schrag, Deborah, additional, and Meyerhardt, Jeffrey A., additional

Published
2012
Full Text
View/download PDF

38. A multi-institutional phase II open-label study of AMG 479 in advanced carcinoid and pancreatic neuroendocrine tumors.

Author

Kulke, Matthew, primary, Chan, Jennifer A., additional, Ryan, David P., additional, Meyerhardt, Jeffrey A., additional, Fuchs, Charles S., additional, Abrams, Thomas Adam, additional, Regan, Eileen, additional, Brady, Rachel, additional, Weber, Jill M., additional, Campos, Tiffany, additional, Kvols, Larry, additional, and Strosberg, Jonathan R., additional

Published
2012
Full Text
View/download PDF

39. Clinical, pharmacodynamic (PD), and pharmacokinetic (PK) evaluation of cediranib in advanced hepatocellular carcinoma (HCC): A phase II study (CTEP 7147).

Author

Zhu, Andrew X., primary, Ancukiewicz, Marek, additional, Supko, Jeffrey G., additional, Blaszkowsky, Lawrence Scott, additional, Meyerhardt, Jeffrey A., additional, Abrams, Thomas Adam, additional, McCleary, Nadine Jackson, additional, Bhargava, Pankaj, additional, Fuchs, Charles S., additional, Ryan, David P., additional, Jain, Rakesh K., additional, and Duda, Dan G., additional

Published
2012
Full Text
View/download PDF

42. Multicenter phase Ib/II study of everolimus (RAD001) and tivozanib (AV-951) in patients with refractory, metastatic colorectal cancer.

Author

Wolpin, Brian M., primary, Ng, Kimmie, additional, Zhu, Andrew X., additional, Abrams, Thomas Adam, additional, Enzinger, Peter C., additional, McCleary, Nadine, additional, Meyerhardt, Jeffrey A., additional, Schrag, Deborah, additional, Kwak, Eunice Lee, additional, Allen, Jill N., additional, Bhargava, Pankaj, additional, Chan, Jennifer A., additional, Goessling, Wolfram, additional, Blaszkowsky, Lawrence Scott, additional, Elliott, Meaghan, additional, Shellock, Maria, additional, Regan, Eileen, additional, and Fuchs, Charles S., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results